➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: September 20, 2021

DrugPatentWatch Database Preview

Details for Patent: 10,793,893

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 10,793,893 protect, and when does it expire?

Patent 10,793,893 protects FIRDAPSE and is included in one NDA.

This patent has two patent family members in two countries.

Summary for Patent: 10,793,893
Title:Methods of administering 3,4-diaminopyridine
Abstract: Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.
Inventor(s): Garovoy; Marvin R. (San Anselmo, CA), Haroldsen; Peter E. (Pacifica, CA), Musson; Donald G. (Greenbrae, CA)
Assignee: SERB SA (Brussels, BE)
Application Number:14/128,672
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 10,793,893

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Catalyst Pharms FIRDAPSE amifampridine phosphate TABLET;ORAL 208078-001 Nov 28, 2018 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial METHOD OF TREATING LAMBERT-EATON MYASTHENIC SYNDROME WITH AMIFAMPRIDINE ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 10,793,893

PCT Information
PCT FiledJune 29, 2012PCT Application Number:PCT/US2012/044904
PCT Publication Date:January 03, 2013PCT Publication Number: WO2013/003708

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.